Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Oct 6:103:adv14153.
doi: 10.2340/actadv.v103.14153.

Impact of Baricitinib on Patients' Quality of Life after One Year of Treatment for Atopic Dermatitis in Real-World Practice: Results of the Observatory of Chronic Inflammatory Skin Diseases Registry

Ziad Reguiai  1 , Pierre André Becherel  2 , Jean Luc Perrot  3 , Anne Claire Fougerousse  4 , Edouard Begon  5 , Claire Poreaux  6 , Claire Boulard  7 , Guillaume Chaby  8 , Charlotte Fite  9 , Inès Zaraa  9 , Dominique Lons-Danic  9 , Anne-Laure Liegeon  10 , Josiane Parier  11 , Nathalie Quiles-Tsimaratos  12 , Laurene David  12 , François Maccari  13
Affiliations

Impact of Baricitinib on Patients' Quality of Life after One Year of Treatment for Atopic Dermatitis in Real-World Practice: Results of the Observatory of Chronic Inflammatory Skin Diseases Registry

Ziad Reguiai et al. Acta Derm Venereol. .

Abstract

The efficacy and safety of baricitinib for treatment of atopic dermatitis have been demonstrated in clinical trials; however, very few real-life studies have been published to date. The Observatory of Chronic Inflammatory Skin Diseases (OMCCI) registry was initiated to prospectively determine the long-term impairment caused by chronic inflammatory dermatoses on patients' lives. The study included 88 patients starting baricitinib for treatment of atopic dermatitis. Clinical evaluation and patient-reported outcomes were recorded at baseline and after 6 and 12 months. After 6 months and 1 year of follow-up, 65 and 47 patients, respectively, were still being treated with baricitinib. Treatment failure was the main reason for discontinuation. Only 1 patient stopped baricitinib because of a side-effect. After 1 year of follow-up, the mean Eczema Area and Severity Index score decreased significantly from 20.7 to 6.4; the percentage of patients with severe atopic dermatitis decreased from 42.9% to 6.5% and a significant improvement in most patient-reported outcomes was noted. There was no difference in terms of efficacy whether or not patients were previously treated with dupilumab. The results remained stable after 6 and 12 months of treatment, which suggests a sustained efficacy of the treatment in patients who initially responded well.

PubMed Disclaimer

Conflict of interest statement

ZR has received consulting fees and honoraria from: Abbvie, Almirall, Amgen, Avene, BMS, Celgene, GSK, Janssen-Cilag, Leo-Pharma, Lilly, Medac, MSD, Novartis, Pierre Fabre Dermatologie, Pfizer, UCB, Sanofi. Investigator for: AbbVie, Actelion, Almirall, Amgen, Bayer, Boehringer-Ingelheim, BMS, Forward Pharma, GSK, Galderma, Genentec, Incyte, Janssen Cilag, Leo-Pharma, Novartis, Pfizer, Roche, Regeneron, UCB, Sanofi. PAB has received consultant and/or member of boards and/or speaker fees from: AbbVie, Amgen, Boehringer-Ingelheim, Bristol-Myers-Squibb, Celgene, Janssen, Léo-pharma, Lilly, Novartis, Pfizer, Sanofi, UCB. JLP has received consultant fees from: Sanofi, Lilly, Leo, Pharma, Pfizer. A-CF has received speaker, consultant or investigator fees from: AbbVie, Leo-Pharma, Lilly, Pfizer, Sanofi. EB: Lilly, AbbVie, UCB, Novartis, Sanofi, Janssen. CB: AbbVie, Janssen, Leo Pharma, Novartis, Sanofi, UCB, Lilly, Almirall. CF: AbbVie, Sanofi, Janssen, UCB, Novartis, Almirall, Lilly. IZ: AbbVie, Novatis, Lilly, Leo, Sanofi, UCB, Janssen, Almirall. DL-D: AbbVie, Almirall, Janssen, Leo Pharma, Lilly, Sanofi, UCB. A-LL: Novartis, Janssen, UCB, AbbVie. JP: Leo, Amgen, UCB, Almirall, Janssen, AbbVie, Novartis, Medac, Lilly, Sanofi. NQ-T: AbbVie, Amgen, BMS, Janssen Cilag, Léo Pharma, Lilly, Novartis. FM has received consulting fees from: Almirall, AbbVie, Leo Pharma, Lilly, Pfizer, Sanofi. GC: Abbvie, Pfizer, Janssen, UCB. CP and LD have no conflicts of interest to declare.

Figures

Fig. 1
Fig. 1
Percentage of patients with mild/moderate/severe atopic dermatitis at baricitinib initiation and after 12 months of treatment according to the Eczema Area and Severity Index (EASI) score. *Missing data = 1
Fig. 2
Fig. 2
Dermatology Life Quality Index (DLQI) score at baseline and after 6 months and 12 months of baricitinib treatment. J0: starting of baricitinib treatment; M6: 6 months after starting baricitinib treatment; M12: 12 months after starting baricitinib treatment.
Fig. 3
Fig. 3
Overall impact of atopic dermatitis on patients’ lives. Patients’ response to the question: When you think about your current skin problem, how troublesome do you consider it? J0: starting baricitinib treatment; M6: 6 months after starting baricitinib treatment; M12: 12 months after starting baricitinib treatment.
See this image and copyright information in PMC

References

    1. Richard MA, Corgibet F, Beylot-Barry M, Barbaud A, Bodemer C, Chaussade V, et al. . Sex- and age-adjusted prevalence estimates of five chronic inflammatory skin diseases in France: results of the “Objectifs Peau” study. J Eur Acad Dermatol Venereol 2018; 32: 1967–1971. - PubMed
    1. Barbarot S, Auziere S, Gadkari A, Girolomoni G, Puig L, Simpson EL, et al. . Epidemiology of atopic dermatitis in adults: results from an international survey. Allergy 2018; 73: 1284–1293. - PubMed
    1. Simpson EL, Bieber T, Eckert L, Wu R, Ardeleanu M, Graham NM, et al. . Patient burden of moderate to severe atopic dermatitis (AD): insights from a phase 2b clinical trial of dupilumab in adults. J Am Acad Dermatol 2016; 74: 491–498. - PubMed
    1. Eckert L, Gupta S, Amand C, Gadkari A, Mahajan P, Gelfand JM. The burden of atopic dermatitis in US adults: health care resource utilization data from the 2013 National Health and Wellness Survey. J Am Acad Dermatol 2018; 78: 54–61.e1. - PubMed
    1. Simpson EL, Lacour JP, Spelman L, Galimberti R, Eichenfield LF, Bissonnette R, et al. . Baricitinib in patients with moderate-to-severe atopic dermatitis and inadequate response to topical corticosteroids: results from two randomized monotherapy phase III trials. Br J Dermatol 2020; 183: 242–255. - PubMed

LinkOut - more resources